Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, announced today its abstract has been accepted to be presented ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results